S.B. No. 2674 amends the Texas Insurance Code to require health benefit plans to provide coverage for biomarker testing aimed at diagnosing, treating, managing, or monitoring an enrollee's disease or condition. Notably, the bill expands the scope of coverage to include biomarker testing for enrollees who have received an organ transplant. The coverage is contingent upon the test being supported by specific medical and scientific evidence, such as FDA-approved tests, national coverage determinations, recognized clinical guidelines, or consensus statements.

The bill also includes provisions for state agencies to seek necessary waivers or authorizations from federal agencies before implementing any part of the Act. The changes will apply only to health benefit plans that are delivered, issued for delivery, or renewed on or after January 1, 2026, while plans renewed before this date will continue to be governed by the previous law. The Act is set to take effect on September 1, 2025.

Statutes affected:
Introduced: Insurance Code 1372.003 (Insurance Code 1372)